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Abstract
We present a meta–analysis of independent studies on the potential implication in the occur-
rence of coronary heart disease (CHD) of the single–nucleotide polymorphism (SNP) at the –308
position of the tumor necrosis factor alpha (TNF–α) gene. We use Bayesian analysis to integrate
independent data sets and to infer statistically robust measurements of correlation. Bayesian hy-
pothesis testing indicates that there is no preference for the hypothesis that the –308 TNF–α SNP
is related to the occurrence of CHD, in the Caucasian or in the Asian population, over the null
hypothesis. As a measure of correlation, we use the probability of occurrence of CHD conditional
on the presence of the SNP, derived as the posterior probability of the Bayesian meta–analysis. The
conditional probability indicates that CHD is not more likely to occur when the SNP is present,
which suggests that the –308 TNF–α SNP is not implicated in the occurrence of CHD.
a Email: cscarvalho@oal.ul.pt
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I. INTRODUCTION
Coronary heart disease (CHD) is now widely accepted to consist of a chronic inflamma-
tory disease [1]. CHD is a complex disease with multifold etiology, with both genetic and
environmental factors contributing to its occurrence and development.
Among the genetic factors potentially implicated in the emergence of CHD, the tumor
necrosis factor alpha (TNF–α) has attracted a great interest for its involvement in the
inflammatory response of the immune system [2]. There is evidence that TNF-α is implicated
in an increased susceptibility to the pathogenesis of a variety of diseases. In particular, high
serum levels of TNF–α affect endothelial cell hemostatic function and hence may modify
the risk for developing CHD [3]. There is also the suggestion that the TNF–α gene affects
the modulation of lipid metabolism, obesity susceptibility and insulin resistance, thus being
potentially implicated in the development of CHD (see Ref. [4] and references therein).
Among the several single–nucleotide polymorphisms (SNPs) that have been identified in
the human TNF-α, the best documented one is at the position –308 of the TNF–α gene
promoter. This SNP involves the substitution of guanine (G) for adenine (A) and the
subsequent creation of two alleles (TNF1(A) and TNF2(G)) and three genotypes (GG, GA
and AA) [5]. It has been hypothesised that the TNF–α SNP could change the susceptibility
to CHD. However, the results on its association with CHD are contradictory, some implying
different influence of the two alleles on the prevalence of CHD, others implying no association
(see Ref. [6] and references therein).
In order to infer the risk of CHD derived from potential risk factors, it is important to
develop a formalism that infers correlations among different intervening factors and combines
independent data sets for a consistent inference of the correlations. In Ref. [8] we introduced
a formalism based on Bayesian inference to infer the correlation of the occurrence of CHD
with two risk factors and tested a simplistic model for the signal pathway on the three–
variable data set from Ref. [9]. In this manuscript we extend the formalism to extract
information from the combination of data from independent studies and to quantify the
combined risk of occurrence of CHD from the –308 TNF–α SNP.
The most exhaustive meta–analysis to date on this correlation is the frequentist analysis
in Ref. [6] covering Caucasian, Asian, Indian and African populations. This meta–analysis
found a 1.5 fold increased risk of developing CHD when the SNP is present in the Caucasian
population, but found no association in the other ethnicities. A more recent meta–analysis,
covering the same data sets, found no association in the Caucasian or in the Asian population
[7].
In this manuscript we propose a meta–analysis based on Bayesian analysis in an attempt
to establish the potential implication of –308 TNF–α SNP in the occurrence of CHD. This
manuscript is organized as follows. In Section II we describe the method. In particular,
in Subsection II A we describe the data sets selected; in Subsection II B we propose two
hypotheses and test which best and most simply describes the data. In Section III we
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perform the Bayesian analysis of the selected data sets, combined by ethnicity and CHD
phenotype, and present the results. In particular, in Subsection III A we infer the conditional
probabilities for the occurrence of CHD given the presence of the SNP; in Subsection III B
we test the sensitivity of this formalism to low–significance data sets, to data sets with
extreme results and to extreme data sets. Finally in Section IV we draw the conclusions.
Below there follows a flow chart describing summarily the reasoning of this meta–analysis
(Fig.s 1,2, and 3).
DATA SELECTION
Select studies
Compute fraction of
SNP in population of
CHD patients, fSNPinCHD
Compute fraction of SNP
in population of non–
CHD patients, fSNPinCHD
Ratio fSNPinCHD/fSNPinCHD
indicates correlation sign
HYPOTHESES TESTING
Define hypothesis H0 : pres-
ence of SNP is unrelated
to occurrence of CHD
Define hypothesis H1 :
presence of SNP is related
to occurrence of CHD
Compute evidence of each
hypothesis, P (DSNP|H0)
and P (DSNP|H1)
Ratio of evidence B10 indicates
which hypothesis is favoured by data
Compute B10 as function of
ratio fSNPinCHD/fSNPinCHD
to complement hypothesis
testing with correlation sign
Figure 1. Flow Chart. Panel 1 of 3. Ellipses indicate the main actions. Rectangles indicate
detailed actions. Rectangles with rounded corners indicate the main results.
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INFERENCE OF CONDI-
TIONAL PROBABILITIES
Define prior probability of
occurrence of CHD, P (CHD)
Compute likelihood of data
assuming a probability distri-
bution for CHD and non–CHD
patients, P (DSNP|CHD,Hi)
and P (DSNP|CHD, Hi)
Compute probability that
randomly selected patient has
SNP, P (nextSNP|DSNP, Hi)
Compute probability that CHD
will occur given that SNP is
present in randomly selected
patient, P (CHD|nextSNP, Hi)
Ratio
P (nextSNP,CHD|DSNP)/P (nextSNP|DSNP,Hi)
quantifies influence of CHD in presence of SNP
Ratio P (CHD|nextSNP, Hi)/P (CHD|DSNP,Hi)
quantifies influence of SNP
in occurrence of CHD
Figure 2. Flow Chart. Panel 2 of 3.
II. METHODS
A. Data Selection
This analysis is based on twenty data sets (indexed i) on two CHD phenotypes (indexed j)
selected from the studies compiled in Ref. [6], following a well–documented study identifica-
tion, data acquisition and selection strategy, including also statistical tests (Hardy–Weinberg
equilibrium, heterogeneity, publication bias). The selected data sets are the studies that re-
port the genotypes of both CHD patients and non–CHD (control) patients for the two CHD
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SENSITIVITY OF RESULTS
Repeat calculations by ex-
cluding: a) low–significant
data sets + data with extreme
results; b) extreme data sets
Proof of formalism’s robustness
Figure 3. Flow Chart. Panel 3 of 3.
phenotypes separately. In particular, there were included: fifteen data sets from studies on
Caucasians, where six studies are on the CHD phenotype coronary stenosis (CS) [9–14] and
nine studies are on the CHD phenotype myocardial infarction (MI) [15–22]; and five data
sets from studies on Asians on the CHD phenotype coronary stenosis [23–27]. The rejected
data sets are: three studies on Caucasians (for not reporting data on non–CHD patients);
four studies on Asians (three for not reporting data on non–CHD patients and one for not
separating the CHD phenotypes); the study on Indians and the study on Africans (both for
not separating the CHD phenotypes).
The data consist of frequencies of occurrence of the –308 TNF–α SNP in randomly
selected CHD patients and non–CHD (control) patients, respectively nSNP,CHD and nSNP,CHD.
The data are summarized in Table I (columns 3–6). The errors indicated were computed
from error propagation. Assuming that the methods for measuring the presence of the SNP
have a success rate of rsuc = 0.88 [31], and furthermore that the error of a counting result
is given by the Poisson approximation
√
n, then the error of a counting result n on the
presence of the SNP is given by (1− rsuc)
√
n/2.
1. Data heterogeneity
In order to investigate the heterogeneity in the data sets, we compare the size of the effect
(defined as a measure of the difference between CHD and non–CHD patients) in each study
[28]. As a measure of the size of the effect, we use the fraction of SNP in the population
of CHD patients and in the population of non–CHD patients, respectively fSNPinCHD =
nSNP,CHD/nCHD and fSNPinCHD = nSNP,CHD/nCHD, where nCHD = nSNP,CHD + nSNP,CHD is
the total number of CHD patients and nCHD = nSNP,CHD + nSNP,CHD is the total number
of non–CHD patients. Moreover, the ratio of these two fractions gives an indication of the
correlation sign. Hence, if fSNPinCHD/fSNPinCHD > 1, the SNP is proportionally more frequent
in CHD than in non–CHD patients, hence the study favours a positive correlation between
5
Study Phenotype CHD patients Controls Bayes factor
(i) (j) GG GA/AA GG GA/AA (H i,j1 /H
i,j
0 ) (H
j
1/H
j
0)
Allen et al. (NA)
Cauc CS
127 53 222 107 0.14± 0.05
0.049± 0.014Elahi et al. (A) 59 38 41 54 3.54± 1.12
Georges et al. (A) 613 236 222 92 0.08± 0.03
0.041± 0.016∗
Sbarsi et al. (A) 175 73 185 56 0.33± 0.11
Szalai et al. (A) 229 89 181 87 0.19± 0.07 0.048± 0.019∗∗
Vendrell et al. (A) 231 110 159 48 1.33± 0.46
Antonicelli (A)
Cauc MI
224 69 246 64 0.12± 0.04
0.026± 0.011
Bennet et al. (A) 799 368 1037 460 0.05± 0.02
Dedoussis et al. (A) 206 31 227 10 26.14± 8.56
Herrmann et al.† (NA) 325 120 376 158 0.11± 0.04
0.035± 0.015∗Herrmann et al.‡ (NA) 117 79 97 79 0.19± 0.06
Koch et al. (NA) 565 228 244 96 0.07± 0.03
0.030± 0.012∗∗
Padovani et al. (A) 120 28 114 34 0.17± 0.06
Tobin et al. (A) 365 182 337 168 0.07± 0.03
Tulyakova et al. (NA) 242 64 177 69 0.60± 0.21
Chen et al. (NA)
Asian CS
29 11 21 9 0.27± 0.08
0.151± 0.057
Hou et al. (NA) 268 32 802 103 0.05± 0.02
Li et al. (NA) 66 8 138 20 0.12± 0.04 0.114± 0.043∗
Liu et al. (A) 234 52 142 34 0.10± 0.03
0.103± 0.037∗∗
Shun et al. (A) 54 19 118 20 1.10± 0.34
Table I. Data sets and results of hypothesis testing. Column 1: Studies selected for the
meta–analysis. The index (A) indicates that a possible association was measured in the original
publication; the index (NA) indicates that no association was measured in the original publication.
Column 2: The phenotype of the patients in the studies grouped by ethnicity. Columns 3–6:
Genotypic frequencies of TNFα–308 in CHD patients and non–CHD (control) patients from twenty
studies (indexed i) and for two CHD phenotypes (indexed j), namely coronary stenosis (CS) and
myocardial infarction (MI). Columns 7–8: The Bayes factors for the hypotheses considered, for
each data set (H i,j1 /H
i,j
0 ), and for the meta–data set of each CHD phenotype (H
j
1/H
j
0).
† French
cohort. ‡ Irish cohort. ∗ Excluding Elahi et al., Dedoussis et al. and Chen et al., respectively for
each phenotype. ∗∗ Excluding Georges et al., Bennet et al. and Hou et al., respectively for each
phenotype.
the presence of the SNP and the occurrence of CHD; if fSNPinCHD/fSNPinCHD < 1, the SNP
is proportionally less frequent in CHD than in non–CHD patients, hence the study favours
a negative correlation; if fSNPinCHD/fSNPinCHD = 1, the SNP is equally frequent in CHD and
in non–CHD patients, hence the study favours no correlation.
We plot this ratio of fractions for each study, grouped by ethnicity and CHD phenotype,
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Figure 4. Funnel plot for the ratio of SNP fractions. The ratio of the fraction of SNP in
the population of CHD patients to the fraction of SNP in the population of non–CHD patients,
fSNPinCHD/fSNPinCHD, for each study, grouped by ethnicity and CHD phenotype. Top panel:
Caucasians with coronary stenosis; Middle panel: Caucasians with myocardial infarction; Bottom
panel: Asians with coronary stenosis. The solid horizontal line is the ratio of the combined data
sets included in each panel. The dashed horizontal line marks the ratio equal to one.
in Fig. 4. We also plot the ratio for the combined data sets included in each panel. We
observe that the ratio of the data sets are asymmetrical distributed about the ratio equal
to one, showing a predominance of ratios smaller than one. The ratio of the combined data
sets included in each panel is slightly smaller than one for the Caucasian studies (for both
CHD phenotypes) and larger than one for the Asian studies. This asymmetry indicates
heterogeneity in the studies, as also observed in the meta–analysis of Ref. [6].
In Fig. 5 (top panel), we plot this ratio of fractions as a function of the sample size. We
observe that smaller data sets are distributed across a wide range of values of this ratio,
whereas larger data sets are distributed more closely to one. This implies that smaller
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Figure 5. Scatter plots as a function of the sample size. Top panel: The ratio of the
frequency of SNP in the CHD population to the frequency of SNP in the non–CHD population as
a function of the sample size. Bottom panel: The Bayes factor for the two hypotheses discussed in
the text as a function of the sample size.
data sets favour either positive or negative correlation, whereas larger data sets favour no
correlation.
B. Hypotheses Testing
First we test the hypothesis H1 that the presence of TNF–α SNP is related to the occur-
rence of CHD against the null hypothesis H0 that the presence of the SNP is unrelated to
the occurrence of CHD. By the Bayes theorem, the probability of a hypothesis Hi given the
data DSNP is the posterior probability of the corresponding hypothesis
P (Hi|DSNP) = P (DSNP|Hi)P (Hi)
P (DSNP)
, (1)
where P (DSNP|Hi) is the evidence, P (Hi) is the prior probability of Hi and P (DSNP) =∑
n P (DSNP|Hi)P (Hi). The subscript in DSNP reminds us that the random variable is the
occurrence of the SNP. In order to infer which hypothesis is more likely in view of the data,
we compare the evidence computed for the two hypotheses. The evidence is the integral of
the likelihood over the j–dimensional parameter space pi,j of the hypothesis Hi
P (DSNP|Hi) =
∫
djpi,j P (DSNP|pi,j, Hi)P (pk,n|Hi). (2)
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Assuming equal prior probabilities for the two hypotheses, then from Eqn. (1) it follows that
P (H1|DSNP)
P (H0|DSNP) =
P (DSNP|H1)
P (DSNP|H0) . (3)
We compute the evidence of the two hypotheses, for each data set separately and for the
combined data sets grouped by CHD phenotype. We follow the procedure detailed in Ref [8],
which we here summarize for one data set and then generalize for the combined data sets. In
all cases, we choose a uniform distribution for the prior of the parameters, which is justified
by the absence of an a priori bias on the values of the parameters [29].
The evidence of H0, P (DSNP|H0), is computed assuming that the presence of the SNP
is described by a binomial distribution with one parameter only, namely the probability p0
that the SNP occurs in a given population. For nSNP occurrences of the SNP and nSNP non–
occurrences of the SNP in a sample of size n = nSNP + nSNP, the likelihood P (DSNP|p0, H0)
is given by
P (DSNP|p0, H0) = pnSNP0 (1− p0)nSNP . (4)
Moreover, assuming a uniform prior distribution for p0, P (p0) = 1, we find that
P (DSNP|H0) =
∫ 1
0
dp0 P (DSNP|p0, H0)P (p0|H0) = nSNP! nSNP!
(nSNP + nSNP + 1)!
, (5)
where n! stands for the factorial of n.
The evidence of H1, P (DSNP|H1), is computed assuming that the presence of the SNP
is described by a binomial distribution with two parameters, namely the probability p1,CHD
that the SNP occurs in the subset of CHD patients and the probability p1,CHD that the SNP
occurs in the subset of non–CHD patients,
P (DSNP|H1) =
∫ 1
0
dp1,CHD
∫ 1
0
dp1,CHD
× P (DSNP|p1,CHD, p1,CHD, H1)P (p1,CHD, p1,CHD|H1). (6)
For nSNP,CHD occurrences of the SNP and nSNP,CHD non–occurrences of the SNP in a subset
of CHD patients nCHD = nSNP,CHD + nSNP,CHD, and also for nSNP,CHD occurrences of the
SNP and nSNP,CHD non–occurrences of the SNP in a subset of non–CHD patients nCHD =
nSNP,CHD + nSNP,CHD, the likelihood P (DSNP|p1,CHD, p1,CHD, H1) is separable, i.e. it can be
decomposed into the product of the likelihoods P (DSNP|p1,CHD, H1) and P (DSNP|p1,CHD, H1),
as follows
P (DSNP|p1,CHD, p1,CHD, H1) = pnSNP,CHD1,CHD (1− p1,CHD)nSNP,CHD
× pnSNP,CHD
1,CHD
(1− p1,CHD)nSNP,CHD
≡ P (DSNP|p1,CHD, H1)P (DSNP|p1,CHD, H1). (7)
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Assuming a uniform probability for p1,CHD and p1,CHD, P (p1,CHD, p1,CHD|H1) =1 and moreover
that the priors on p1,CHD and p1,CHD are separable, the posterior distribution will also be
separable and given by
P (DSNP|H1) =
∫ 1
0
dp1,CHD P (DSNP|p1,CHD, H1)P (p1,CHD|H1)
×
∫ 1
0
dp1,CHD P (DSNP|p1,CHD, H1)P (p1,CHD|H1)
=
nSNP,CHD! nSNP,CHD!
(nSNP,CHD + nSNP,CHD + 1)!
nSNP,CHD! nSNP,CHD!
(nSNP,CHD + nSNP,CHD + 1)!
. (8)
In order to compare the hypotheses, we take the ratio of the corresponding evidences,
B10 = P (H1|D)/P (H0|D), which we present in Table I (columns 7–8). This quantity is
known as the Bayes factor and gives empirical levels of significance for the strength of
the evidence of the test hypothesis over that of the null hypothesis. It also encapsulates
the Occam’s factor, which measures the adequacy of a hypothesis to the data over the
parameter space of the hypothesis [29]. The levels of significance ascribed to the Bayes
factor are calibrated by the Jeffrey’s scale [30]. According to this scale, a Bayes factor larger
than one indicates that H1 is favoured over H0. Otherwise, H0 is favoured over H1. For
the data sets taken separately, the results from this hypothesis test mostly agree with the
corresponding results presented in the meta–analysis by Chu et al. (see Fig. 1 of Ref. [7]).
We plot the Bayes factor for each study, grouped by ethnicity and CHD phenotype, in
Fig. 6. For the data sets taken separately, we observe that the Bayes factor is asymmetrically
distributed about the Bayes factor equal to one, with most Bayes factors being smaller than
one. The exceptions are Elahi et al. [10], Vendrell et al. [9] and Dedoussis et al. [17] for
the Caucasian population, and Shun et al. [27] for the Asian population. This asymmetry
indicates heterogeneity in the results. For the combined data sets included in each panel,
the Bayes factor takes values 0.03 − 0.05 for the Caucasian population and 0.15 for the
Asian population, which indicates that there is no evidence for H1 over H0. We also observe
that, for the Caucasian population, the Bayes factor of the combined data sets is outside the
range of variability of the Bayes factor of the data sets considered separately. This suggests
that the combination of the Caucasian data sets causes a new data pattern to emerge.
Conversely the combination of the Asian data sets leads to an approximately average data
pattern. Hence we conclude that the data favour H0 over H1. Since H0 yields trivial results,
in the subsequent subsections we present the results also for H1 to illustrate the application
of the formalism to a more general setup. It is also instructive to compare the subsequent
results using both hypotheses.
In Fig. 5 (bottom panel), we plot the Bayes factor as a function of the sample size. We
observe that smaller data sets are distributed across a wide range of values of the Bayes
factor, whereas larger data sets are distributed across values smaller than one. This implies
that smaller data sets favour either H0 or H1, whereas larger data sets favour H0.
10
Phenotype = Cauc CS
Experiment
Ba
ye
s 
fa
ct
or
 B
10
Allen Elahi Georges Sbarsi Szalai Vendrell
0.05
0.10
0.20
0.50
1.00
2.00
5.00
Phenotype = Cauc MI
Experiment
Ba
ye
s 
fa
ct
or
 B
10
anton benn dedou herrF herrI koch padov tobin tuly
0.02
0.05
0.10
0.20
0.50
1.00
2.00
5.00
10.00
20.00
50.00
Phenotype = Asian CS
Experiment
Ba
ye
s 
fa
ct
or
 B
10
Chen Hou Li Liu Shun
0.05
0.10
0.20
0.50
1.00
2.00
Figure 6. Funnel plot for the Bayes factor. The Bayes factor for each study, grouped
by ethnicity and CHD phenotype. Top panel: Caucasians with coronary stenosis; Middle panel:
Caucasians with myocardial infarction; Bottom panel: Asians with coronary stenosis. The solid
horizontal line marks the average Bayes factor of the data sets included in each panel. The dashed
horizontal line marks the Bayes factor equal to one.
1. Correlation sign
Comparing Fig. 6 with Fig. 4, we observe that, among the studies with Bayes factor larger
than one, Elahi et al. has a ratio fSNPinCHD/fSNPinCHD < 1, i.e. the SNP is proportionally
less frequent in CHD than in non–CHD patients, which indicates a negative correlation
between the presence SNP and the occurrence of CHD. Another example of comparatively
large Bayes factor and low ratio fSNPinCHD/fSNPinCHD is the study of Tuliakova et al. This
indicates that the hypotheses as formulated do not distinguish the correlation sign.
To further explore how the ratio fSNPinCHD/fSNPinCHD affects the result of the hypothesis
testing, we consider several realizations of CHD populations with the same nCHD but with
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Figure 7. Bayes factor as a function of the frequency of SNP in the CHD populations.
The Bayes factor for several realizations of CHD populations with the same nCHD but with different
fractions of SNP, grouped by ethnicity and CHD phenotype. The realizations that correspond to
a real combined data set are marked as red points. The dashed horizontal line marks the Bayes
factor equal to one. Top panel: The Bayes factor as a function of fSNPinCHD/fSNPinCHD. Bottom
panel: The Bayes factor as a function of fSNPinCHD.
different fractions of SNP. More specifically for each combined data set, we vary nSNP,CHD
while varying simultaneously nSNP,CHD so as to keep nCHD constant. Throughout the dif-
ferent realizations, the size of the control population is kept equal to the size of the control
population of the combined data sets grouped by ethnicity and CHD phenotype. For each
realization, we compute both fSNPinCHD (note that fSNPinCHD is by construction kept fixed)
and B10, and plot the results in Fig. 7. The realizations with the fSNPinCHD of a real com-
bined data set are marked as red points. In the top panel, we plot B10 as a function of
fSNPinCHD/fSNPinCHD, from which there result three parabolae centred at the same point. In
the bottom panel, for a better visualization of the behaviour of B10, we plot B10 as a function
of fSNPinCHD, from which there result three parabolae centred at different points. We observe
that B10 follows a parabola, taking the minimum value when fSNPinCHD/fSNPinCHD = 1 and
increasing in both directions with the increase of |fSNPinCHD/fSNPinCHD − 1|, i.e. with the
increase of the distance from 1. This confirms that the hypotheses as formulated do not dis-
tinguish between a positive correlation of the SNP with CHD (fSNPinCHD/fSNPinCHD > 1) and
a negative correlation (fSNPinCHD/fSNPinCHD < 1). Hence, the value of fSNPinCHD/fSNPinCHD
complements the value of B10 in the characterization of the correlation.
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III. RESULTS
A. Inference of conditional probabilities
1. Posterior probability for the occurrence of CHD
We proceed to compute the probability for the occurrence of (CHD, i.e. given the data
on the presence of the SNP, we determine the probability that a patient has CHD. This is
defined as the posterior probability
P (CHD|DSNP, Hi) = P (DSNP|(CHD,Hi)P (CHD)
P (DSNP|Hi) . (9)
The prior probability P (CHD) is based on the available information on the occurrence of
CHD. This probability can be computed by combining all the risk factors per age interval
per pathology. According to the European guidelines, less than 4 in 1000 people have CS
[32], whereas about 1 in 1000 people have MI [33]. We then use P (CHD) = 0.004 for CS
and P (CHD) = 0.001 for MI.
The evidence P (DSNP|Hi) can be decomposed as
P (DSNP|Hi) = P (DSNP|(CHD,Hi)P (CHD) + P (DSNP|CHD, Hi)P (CHD). (10)
In the case of H0,
P (DSNP|(CHD,H0) =
(
n
nSNP
)
pnSNP0 (1− p0)nSNP ≡ P (DSNP|H0)
P (DSNP|CHD, H0) = P (DSNP|H0), (11)
whereas in the case of H1,
P (DSNP|(CHD,H1) =
(
nCHD
nSNP,CHD
)
p
nSNP,CHD
1,CHD (1− p1,CHD)nSNP,CHD
P (DSNP|CHD, H1) =
(
nCHD
nSNP,CHD
)
p
nSNP,CHD
1,CHD
(1− p1,CHD)nSNP,CHD . (12)
In the previous section, we computed the evidence by marginalizing the parameters of each
hypothesis. Here, assuming a hypothesis Hi and using the Bayes theorem, we compute the
posterior probability of each parameter pi,j given the data
P (pi,j|DSNP) = P (DSNP|pi,j)P (pi,j|Hi)
P (DSNP|Hi) , (13)
and find for pi,j the value that maximizes the likelihood P (DSNP|pi,j). In the case of H0,
we compute the posterior probability of the single parameter pi,j = p0, where P (DSNP|p0)
is given by Eqn. (4), P (DSNP|H0) is given by Eqn. (5) and P (p0|H0) is assumed uniform.
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Taking the derivative with respect to p0 and solving for dP (p0|DSNP)/dp0 = 0, we find for
the maximum–likelihood value of p0 the value
p0(maxL) =
nSNP
(nSNP + nSNP)
. (14)
Similarly in the case of H1, we compute the posterior probability of each of the two pa-
rameters pi,j = {p1,CHD, p1,CHD}, where P (DSNP|p1,CHD) and P (DSNP|p1,CHD) are given by
Eqn. (6), P (DSNP|H1) is given by Eqn. (8) and both P (p1,CHD|H1) and P (p1,CHD|H1) are
assumed uniform, finding for the maximum–likelihood values of p1,CHD and p1,CHD respec-
tively
p1,CHD(maxL) =
nSNP,CHD
(nSNP,CHD + nSNP,CHD)
, (15)
p1,CHD(maxL) =
nSNP,CHD
(nSNP,CHD + nSNP,CHD)
. (16)
Analogously we define the posterior probability
P (CHD|DSNP, Hi) = P (DSNP|CHD, Hi)P (CHD)
P (DSNP|Hi) . (17)
Finally, using the maximum–likelihood value of pi,j, we compute P (CHD|DSNP, Hi) for
the data sets combined, which we present in Table II.
In the case of H0, no information is added to the posterior probability, since by Eqn. (11)
the posterior probabilities equal the prior. Conversely in the case of H1, information is added
to the posterior probability, since by Eqn. (12) there result posterior probabilities different
from the prior albeit compatible with the prior.
2. Prediction of the presence of the SNP
We now proceed to compute the probability for the presence of the SNP, i.e. given the
data, we determine the probability that a randomly selected patient (with or without CHD)
has the SNP. This probability is defined as
P (nextSNP|DSNP, Hi) = P (nextSNP|DSNP,CHD)P (CHD|DSNP, Hi)
+ P (nextSNP|DSNP,CHD)P (CHD|DSNP, Hi)
≡ P (nextSNP,CHD|DSNP, Hi) + P (nextSNP,CHD|DSNP, Hi). (18)
In the case of H0,
P (nextSNP|DSNP,CHD) = P (nextSNP|DSNP,CHD) = p0, (19)
whereas in the case of H1,
P (nextSNP|DSNP,CHD) = p1,CHD,
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Hypothesis Probabilities Phenotype (j)
Cauc CS Cauc MI Asian CS
H0
p0 0.299± 0.001 0.284± 0.001 0.141± 0.001
P (CHD|DSNP, H0) (4.00± 1.31) · 10−3 (1.00± 0.25) · 10−3 (4.00± 0.91) · 10−3
P (nextSNP, CHD|DSNP, H0) (1.19± 0.39) · 10−3 (0.28± 0.07) · 10−3 (0.56± 0.13) · 10−3
P (nextSNP,CHD|DSNP, H0) 0.298± 1.093 0.284± 1.752 0.141± 0.360
P (nextSNP|DSNP, H0) 0.299± 1.093 0.284± 1.572 0.141± 0.360
rnextSNP,CHD (4.00± 14.65) · 10−3 (1.00± 5.54) · 10−3 (4.00± 10.22) · 10−3
H1
p1,CHD 0.295± 0.001 0.283± 0.001 0.158± 0.001
p1,CHD 0.305± 0.001 0.285± 0.001 0.132± 0.001
P (CHD|DSNP, H1) (3.42± 7.94) · 10−3 (0.98± 3.26) · 10−3 (5.00± 7.02) · 10−3
P (nextSNP, CHD|DSNP, H1) (1.00± 2.34) · 10−3 (0.28± 0.92) · 10−3 (0.79± 1.11) · 10−3
P (nextSNP,CHD|DSNP, H1) 0.304± 0.598 0.285± 0.926 0.131± 0.244
P (nextSNP|DSNP, H1) 0.305± 0.598 0.285± 0.926 0.132± 0.244
rnextSNP,CHD (3.30± 10.02) · 10−3 (0.98± 4.54) · 10−3 (6.00± 13.84) · 10−3
Table II. Probabilities inferred from the combined data sets. To each hypothesis there
correspond several rows consisting of : a) the parameters pi,j given by the maximum–likelihood
values, in particular, p0 (hence one row) in the case of H0, p1,CHD and p1,CHD (hence two rows) in
the case of H1; b) the posterior probability for the occurrence of (CHD, P (CHD|DSNP, Hi) (hence
one row for each hypothesis); c) the predicted probabilities for the presence of the SNP, namely
P (nextSNP,CHD|DSNP, Hi), P (nextSNP,CHD|DSNP, Hi) and P (nextSNP|DSNP, Hi) (hence three
rows for each hypothesis); and d) the probability ratio that measures the influence of CHD in the
presence of the SNP, rnextSNP,CHD ≡ P (nextSNP,CHD|DSNP, Hi)/P (nextSNP|DSNP, Hi), com-
puted from the combined data of each phenotype (hence one row for each hypothesis). Column 1:
The hypotheses. Column 2: The inferred quantities, as described above. Columns 3–5: The values
of the inferred quantities for the combined ethnicity and CHD phenotype.
P (nextSNP|DSNP,CHD) = p1,CHD. (20)
Using the maximum–likelihood values of pi,j and the posterior probability P (CHD|DSNP, Hi)
computed above, we compute P (nextSNP|DSNP, Hi), which we present in Table II.
For completion, using the Bayes theorem, we invert P (nextSNP|DSNP,CHD) to find the
probability that CHD will occur given that the SNP is present in a randomly selected patient
P (CHD|nextSNP, Hi) = P (nextSNP|DSNP,CHD)P (CHD|DSNP, Hi)
P (nextSNP|DSNP, Hi) . (21)
Similarly, inverting P (nextSNP|DSNP,CHD), we find the probability that CHD will not
occur given that the SNP is present in a randomly selected patient, P (CHD|nextSNP, Hi),
which can be found simply by replacing CHD by CHD in Eqn. (21).
In order to quantify the influence of CHD in the presence of the SNP, we compute the
ratio of P (nextSNP,CHD|DSNP) to P (nextSNP|DSNP, Hi), which gives an estimate of how
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Hypothesis Probabilities Phenotype (j)
Cauc CS Cauc MI Asian CS
H0
p0 0.288± 0.001 0.296± 0.001 0.136± 0.001
P (CHD|DSNP, H0) (4.00± 1.26) · 10−3 (1.00± 0.24) · 10−3 (4.00± 0.89) · 10−3
P (nextSNP, CHD|DSNP, H0) (1.15± 0.36) · 10−3 (0.30± 0.07) · 10−3 (0.55± 0.12) · 10−3
P (nextSNP,CHD|DSNP, H0) 0.287± 1.018 0.296± 1.605 0.136± 0.340
P (nextSNP|DSNP, H0) 0.289± 1.018 0.296± 1.605 0.136± 0.340
rnextSNP,CHD (4.00± 14.16) · 10−3 (1.00± 5.54) · 10−3 (4.00± 10.00) · 10−3
H1
p1,CHD 0.290± 0.001 0.292± 0.001 0.151± 0.001
p1,CHD 0.287± 0.001 0.300± 0.001 0.128± 0.001
P (CHD|DSNP, H1) (3.34± 7.57) · 10−3 (0.99± 3.18) · 10−3 (5.11± 6.96) · 10−3
P (nextSNP, CHD|DSNP, H1) (0.97± 2.19) · 10−3 (0.29± 0.93) · 10−3 (0.77± 1.05) · 10−3
P (nextSNP,CHD|DSNP, H1) 0.286± 0.542 0.300± 0.947 0.128± 0.234
P (nextSNP|DSNP, H1) 0.287± 0.543 0.300± 0.947 0.129± 0.234
rnextSNP,CHD (3.38± 9.96) · 10−3 (0.96± 4.34) · 10−3 (6.02± 13.67) · 10−3
Table III. Probabilities inferred from the combined data sets excluding the low–
significance data sets and the data sets with extreme results. Excluded: Elanhi et al.
[10], Dedoussis et al. [17] and Chen et al. [23]. Similarly to Table II, to each hypothesis there
correspond several rows consisting of: a) the parameters given by the maximum–likelihood values
(one row in the case of H0 and two rows in the case of H1); b) the posterior probability for the
occurrence of CHD (one row for each hypothesis); c) the predicted probabilities for the presence of
the SNP (three rows for each hypothesis); and d) the probability ratio that measures the influence
of CHD in the presence of the SNP, computed from the combined data of each phenotype (one row
for each hypothesis). Column 1: The hypotheses. Column 2: The inferred quantities, as described
above. Columns 3–5: The values of the inferred quantities for the combined ethnicity and CHD
phenotype.
much the occurrence of CHD indicates the presence of the SNP. This is also the probability
in Eqn. (21). In the case of H0, this ratio equals the posterior probability of occurrence of
CHD. Conversely in the case of H1, this ratio is different from the posterior probability of
occurrence of CHD albeit compatible with it. The occurrence of CHD indicates the presence
of the SNP in of order 0.1% of patients (0.1− 0.4% in the case of H0, 0.1− 0.6% in the case
of H1), which suggests that the occurrence of CHD is not a good marker for the presence of
the SNP.
In order to quantify the influence of the SNP in the occurrence of (CHD, we compute the
ratio of P (CHD|nextSNP, Hi) to P (CHD|DSNP, Hi), which gives an estimate of how much
the presence of the SNP indicates the occurrence of CHD. This is also the probability in
Eqns. (19, 20). The presence of SNP indicates the occurrence of CHD in of order 0.1% of
patients (0.141−0.299.% in the case of H0, 0.158−0.295% in the case of H1), which suggests
that the presence of the SNP is not a risk factor for the emergence of CHD.
16
Hypothesis Probabilities Phenotype (j)
Cauc CS Cauc MI Asian CS
H0
p0 0.308± 0.001 0.271± 0.001 0.177± 0.001
P (CHD|DSNP, H0) (4.00± 1.08) · 10−3 (1.00± 0.20) · 10−3 (4.00± 0.63) · 10−3
P (nextSNP, CHD|DSNP, H0) (1.12± 0.33) · 10−3 (0.27± 0.05) · 10−3 (0.71± 0.11) · 10−3
P (nextSNP,CHD|DSNP, H0) 0.306± 0.923 0.270± 1.220 0.177± 0.314
P (nextSNP|DSNP, H0) 0.308± 0.923 0.271± 1.220 0.177± 0.314
rnextSNP,CHD (4.00± 12.05) · 10−3 (1.00± 4.51) · 10−3 (4.00± 7.11) · 10−3
H1
p1,CHD 0.306± 0.001 0.270± 0.001 0.190± 0.001
p1,CHD 0.309± 0.001 0.271± 0.001 0.165± 0.001
P (CHD|DSNP, H1) (3.93± 6.97) · 10−3 (0.92± 2.58) · 10−3 (3.90± 4.35) · 10−3
P (nextSNP, CHD|DSNP, H1) (1.20± 2.14) · 10−3 (0.25± 0.70) · 10−3 (0.74± 0.828) · 10−3
P (nextSNP,CHD|DSNP, H1) 0.308± 0.535 0.271± 0.698 0.165± 0.187
P (nextSNP|DSNP, H1) 0.309± 0.535 0.271± 0.698 0.165± 0.187
rnextSNP,CHD (3.90± 9.68) · 10−3 (0.91± 3.48) · 10−3 (4.48± 7.13) · 10−3
Table IV. Probabilities inferred from the combined data sets excluding the extreme
data sets. Excluded: Georges e tal. [12], Bennet el al. [16] and Hou et al. [24]. Similarly to
Table II, to each hypothesis there correspond several rows consisting of: a) the parameters given
by the maximum–likelihood values (one row in the case of H0 and two rows in the case of H1); b)
the posterior probability for the occurrence of CHD (one row for each hypothesis); c) the predicted
probabilities for the presence of the SNP (three rows for each hypothesis); and d) the probability
ratio that measures the influence of CHD in the presence of the SNP, computed from the combined
data of each phenotype (one row for each hypothesis). Column 1: The hypotheses. Column 2: The
inferred quantities, as described above. Columns 3–5: The values of the inferred quantities for the
combined ethnicity and CHD phenotype.
B. Sensitivity of the results
To test the robustness of this meta–analysis, we conceive two tests of the sensitivity of
the results, namely to low–significance data sets, to data sets with extreme results and to
extreme data sets.
To test the sensitivity of the results to low–significance data sets, we exclude the data sets
with comparatively small sample sizes for the same CHD phenotype, namely the study by
Elanhi et al. [10] and the study by Chen et al. [23], from the combination. We also exclude
the studies with extreme results (i.e., the studies with the largest Bayes factor), namely
the study in Dedoussis et al. [17]. We recompute both the Bayes factors (Table I) and the
probabilities of CHD (Table III). We observe that the Bayes factor in the new combination
changes by 18%, −38% and 24%, respectively for the CS Caucasian, the MI Caucasian and
the CS Asian population. The inferred parameters and probabilities vary by −6 to 6%, −5
to 2%, and −1 to 4%, respectively for the CS Caucasian, the MI Caucasian and the CS
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Asian population. The largest difference is observed for the CS Caucasian population due
to the exclusion of the study by Elanhi et al. [10]. The exclusion of the study by Dedoussis
et al. [17] from the MI Caucasian population causes predominantly negative differences.
To test the sensitivity of the results to extreme data sets, we exclude the data sets
with comparatively large samples sizes for the same CHD phenotype, namely the study by
Georges et al. [12], the study by Bennet el al. [16] and the study by Hou et al. [24], from
the combination. These are also the studies with the smallest Bayes factor for each CHD
phenotype. We recompute both the Bayes factors (Table I) and the probabilities of CHD
(Table IV). We observe that the Bayes factor in the new combination changes by 3%, −19%
and 32%, respectively for the CS Caucasian, the MI Caucasian and the CS Asian population.
The inferred parameters and probabilities vary by −20 to −1%, 5 to 11%, and −26 to 25%,
respectively for the CS Caucasian, the MI Caucasian and the CS Asian population. The
largest difference is observed for the CS Asian population due to the exclusion of the study
by Hou et al. [24]. The exclusion of the study by Georges et al. [12] from the CS Caucasian
population causes predominantly negative differences.
In both tests, the differences in the Bayes factor leave the result of the hypothesis testings
unchanged, while the differences in the inferred parameters and probabilities also leave the
conclusions unchanged. We thus infer that this formalism is largely insensitive to a) low–
significante data sets combined with data with extreme results, and to b) extreme data sets,
which renders this formalism significantly robust.
IV. CONCLUSIONS
In this manuscript we investigated the correlation between the occurrence of CHD with
the presence of the –308 TNF–α SNP from fifteen independent data sets on Caucasians for
two CHD phenotypes and from five independent data sets on Asian for one CHD phenotype.
We showed how to combine independent data sets and to infer correlations using Bayesian
analysis.
Hypothesis testing on the combined data sets indicated that there is no evidence for a cor-
relation between the occurrence of CHD and the presence of the SNP, either on Caucasians
or on Asians. This result agrees with previous meta–analyses [6, 7]. As a measure of an
eventual correlation, we computed the conditional probability of CHD given the SNP, nor-
malized to the probability that CHD occurs, finding that the presence of the SNP indicates
the occurrence of CHD in of order 0.1% of patients, i.e. in of order 0.1% of the occurrence of
CHD is concomitant with the presence of SNP. We also tested the sensitivity of the results
by excluding selected data sets from the meta–analysis. We found changes of order 10%,
leaving the results unchanged and thus establishing this formalism as significantly robust.
An interesting extension of this work for the sake of completion is the inclusion of stud-
ies referring to Africans and Indians which are currently too few to extract convincing results.
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